Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 3/20 | 0.54 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.45 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.45 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.45 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.45 |
| ▸ | FAAH | O00519 | 8/20 | 0.43 |
| ▸ | CES1 | P23141 | 5/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.39 |
| ▸ | LPAR3 | Q9UBY5 | 1/20 | 0.39 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.39 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8218831 | 0.93 | CES2 (0.63) | CES2S1PR2S1PR4S1PR1S1PR3 | |
| SCHEMBL28151371 | 0.91 | CES2 (0.67) | CES2S1PR2S1PR4S1PR1S1PR3 | |
| SCHEMBL26293737 | 0.91 | CES2 (0.67) | CES2S1PR2S1PR4S1PR1S1PR3 | |
| SCHEMBL10623101 | 0.91 | CES2 (0.67) | CES2S1PR2S1PR4S1PR1S1PR3 | |
| SCHEMBL31190476 | 0.91 | CES2 (0.67) | CES2S1PR2S1PR4S1PR1S1PR3 | |
| SCHEMBL25802000 | 0.91 | CES2 (0.67) | CES2S1PR2S1PR4S1PR1S1PR3 | |
| SCHEMBL249345 | 0.84 | — | — | |
| SCHEMBL15948817 | 0.81 | CES2 (0.48) | CES2S1PR2S1PR4S1PR1S1PR3 | |
| SCHEMBL28365282 | 0.80 | FAAH (0.57) | CES2FAAHCES1CYP1A2KMT2A | |
| SCHEMBL28405075 | 0.80 | F7 (0.55) | CES2FAAHCES1CYP1A2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3913720-B1 | ELECTROCHEMICAL DEVICE AND ELECTRONIC DEVICE COMPRISING SAME | NINGDE AMPEREX TECHNOLOGY LTD (CN) | 2024-09-04 | — | — | EP | claimed |
| US-12617747-B2 | Cannabinoid analogs and methods for their preparation | INMED PHARMACEUTICALS INC. (CA) | 2026-05-05 | — | — | US | disclosed |
| EP-4658667-A1 | CYCLIC PEPTIDES FOR INHIBITING TNF RECEPTOR 1 ACTIVITY | Merck Sharp & Dohme LLC (US) | 2025-12-10 | — | — | EP | disclosed |
| WO-2025072539-A1 | AMINO ACID COMPOUNDS WITH NITROGEN LINKERS AND USES THEREOF | PLIANT THERAPEUTICS, INC. (US) | 2025-04-03 | — | — | WO | disclosed |
| WO-2024163691-A1 | CYCLIC PEPTIDES FOR INHIBITING TNF RECEPTOR 1 ACTIVITY | MERCK SHARP & DOHME LLC (US) | 2024-08-08 | — | — | WO | disclosed |
| CN-115668569-A | Electrolyte solution, electrochemical device, lithium ion secondary battery, and assembly | 大金工业株式会社 | 2023-01-31 | — | — | CN | disclosed |
| CN-115668571-A | Electrolyte solution, electrochemical device, lithium ion secondary battery, module, and compound | 大金工业株式会社 | 2023-01-31 | — | — | CN | disclosed |
| US-11534434-B2 | Xanomeline derivatives and methods for treating neurological disorders | Karuna Therapeutics, Inc. (US) | 2022-12-27 | — | — | US | disclosed |
| US-11480878-B2 | Monomers, polymers and photoresist compositions | ROHM AND HAAS ELECTRONIC MATERIALS KOREA LTD. (KR) | 2022-10-25 | — | — | US | disclosed |
| US-20210403408-A1 | CANNABINOID ANALOGS AND METHODS FOR THEIR PREPARATION | INMED PHARMACEUTICALS INC. (CA) | 2021-12-30 | — | — | US | disclosed |
| CN-105209457-A | Pyrrolidine derivatives, pharmaceutical compositions containing them, and their use in therapy | ABBVIE DEUTSCHLAND | 2015-12-30 | — | — | CN | disclosed |
| WO-2014140310-A1 | PYRROLIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | AbbVie Deutschland GmbH & Co. KG (DE) | 2014-09-18 | — | — | WO | disclosed |
| US-20140275087-A1 | PYRROLIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | AbbVie Deutschland GmbH & Co. KG (DE) | 2014-09-18 | — | — | US | disclosed |
| US-20140275086-A1 | PYRROLIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | AbbVie Deutschland GmbH & Co. KG (DE) | 2014-09-18 | — | — | US | disclosed |
| EP-2440198-A2 | HALOGENATED ALIPHATIC CARBOXYLIC ACIDS, OLIGOMERS AND/OR POLYMERS THEREOF AND THEIR USE IN DEVITALIZING EXTERNAL AND INTERNAL NEOPLASMS | Mardi Medicines Ltd. (IL) | 2012-04-18 | — | — | EP | disclosed |
| CN-102241587-A | Synthesis method of ethyl 2,2-difluorohexanoate | SHANGHAI FLUOROTECH SCIENT CO LTD | 2011-11-16 | — | — | CN | disclosed |
| US-20110052641-A1 | HALOGENATED ALIPHATIC CARBOXYLIC ACIDS, OLIGOMERS AND/OR POLYMERS THEREOF AND THEIR USE IN DEVITALIZING EXTERNAL AND INTERNAL NEOPLASMS | MARDI MEDICINES LTD. (IL) | 2011-03-03 | — | — | US | disclosed |
| WO-2010143188-A2 | HALOGENATED ALIPHATIC CARBOXYLIC ACIDS, OLIGOMERS AND/OR POLYMERS THEREOF AND THEIR USE IN DEVITALIZING EXTERNAL AND INTERNAL NEOPLASMS | MARDI MEDICINES LTD. (IL) | 2010-12-16 | — | — | WO | disclosed |
| US-4323547-A | INVESTIGATING THE DINETICS OF HEART MUSCLE METABOLISM | KERNFORSCHUNGSANLAGE JULICH GMBH (DE) | 1982-04-06 | — | — | US | disclosed |
| US-4076911-A | PALLADIUM CYANIDE CATALYST | UNION OIL COMPANY OF CALIFORNIA (US) | 1978-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12617747-B2 | Cannabinoid analogs and methods for their preparation | CNR2, CNR1, FAAH | CES2 248/4885S1PR2 479/4885S1PR4 883/4885 |
| US-20140275086-A1 | PYRROLIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | SLC6A7, GFPT1, SUGT1 | CES2 876/4885S1PR2 1463/4885S1PR4 2361/4885 |
| US-11534434-B2 | Xanomeline derivatives and methods for treating neurological disorders | CHRM1, RXFP3, NPY5R | CES2 1335/4885S1PR2 2143/4885S1PR4 2346/4885 |
| US-11480878-B2 | Monomers, polymers and photoresist compositions | PARG, LCP1, ALG3 | CES2 1510/4885S1PR2 3737/4885S1PR4 4009/4885 |
| US-20210403408-A1 | CANNABINOID ANALOGS AND METHODS FOR THEIR PREPARATION | CNR1, CNR2, ERG28 | CES2 162/4885S1PR2 1342/4885S1PR4 1216/4885 |
| US-20140275087-A1 | PYRROLIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | SLC6A7, GFPT1, SUGT1 | CES2 876/4885S1PR2 1463/4885S1PR4 2361/4885 |
| US-20110052641-A1 | HALOGENATED ALIPHATIC CARBOXYLIC ACIDS, OLIGOMERS AND/OR POLYMERS THEREOF AND THEIR USE IN DEVITALIZING EXTERNAL AND INTERNAL NEOPLASMS | CCR10, PBK, CCR3 | CES2 944/4885S1PR2 2698/4885S1PR4 2383/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.